TatyanaAFeldmanMD

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Physician

Overview of Dr. Feldman

As an attending physician in the Lymphoma Division and director of the T-Cell Lymphoma Program at John Theurer Cancer Center, I am optimistic that current research into intercellular mechanisms can generate effective new therapies for treating this rare type of lymphoma. Immunotherapy, specifically CAR-T 19 cells that are genetically modified to attack lymphoma cells, is an especially exciting new approach.

Office
92 Second Street
Hackensack, NJ 07601
Book by Phone+1(903) 600-8606
Is this information wrong?

Education & Training

NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2001
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1999 - 2000
Icahn School of Medicine at Mount Sinai (Beth Israel)Residency, Internal Medicine, 1995 - 1999
Minsk Medical InstituteClass of 1992

Certifications & Licensure

DC State Medical License 2019 - 2024
NY State Medical License 1998 - 2024
NJ State Medical License 2002 - 2023
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

New York Magazine: Top Doctors Castle Connolly, 2016
Top Doctors: New York Metro Area Castle Connolly, 2014
Inside Jersey Top Doctors for Cancer Castle Connolly, 2014
Inside Jersey Magazine Top Doctors Castle Connolly, 2013-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Join now to see all

Clinical Trials

Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL Start of enrollment: 2010 Jun 01
Unknown status
Phase 1, Phase 2
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Start of enrollment: 2012 Jun 01
Completed
Phase 2
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2013 May 01
Completed
Phase 1
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma Start of enrollment: 2014 Sep 01
Terminated
Phase 2
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Start of enrollment: 2016 Jun 17
Recruiting
Phase 2
Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence Start of enrollment: 2016 Jun 07
Active, not recruiting
Phase 1, Phase 2
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma Start of enrollment: 2016 Feb 01
Terminated
Phase 1
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome Start of enrollment: 2016 Oct 01
Recruiting
A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2017 Sep 05
Active, not recruiting
Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2017 Nov 27
Recruiting
Phase 1, Phase 2
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies Start of enrollment: 2018 Mar 29
Recruiting
Phase 1, Phase 2
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type Start of enrollment: 2018 Nov 09
Recruiting
Phase 2
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma Start of enrollment: 2019 Mar 12
Completed
Phase 1, Phase 2
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma Start of enrollment: 2018 Nov 28
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

7 citations
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
Joanna Zurko, Jeremy Ramdial, Mazyar Shadman, Sairah Ahmed, Aniko Szabo, Lorenzo Iovino, Ana Alarcon Tomas, Craig Sauter, Miguel-Angel Perales, Nirav N Shah, Utkarsh H...> ;Haematologica. 2023 Jan 1
5 citations
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Catherine Thieblemont, Tycel Phillips, Herve Ghesquieres, Chan Y Cheah, Michael Roost Clausen, David Cunningham, Young Rok Do, Tatyana Feldman, Robin Gasiorowski, Wojc...> ;Journal of Clinical Oncology. 2023 Apr 20
2 citations
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre,...
Alex F Herrera, Lu Chen, Yago Nieto, Leona Holmberg, Patrick Johnston, Matthew Mei, Leslie Popplewell, Saro Armenian, Thai Cao, Leonardo Farol, Firoozeh Sahebi, Ricard...> ;The Lancet. Haematology. 2023 Jan 1
1 citations
Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era.
Alexandra Della Pia, Charles Zhao, Parul Jandir, Amolika Gupta, Mark Batistick, Gee Youn Geeny Kim, Yi Xia, Jaeil Ahn, Gabriella Magarelli, Brittany Lukasik, Lori A Le...> ;Cancers. 2022 Aug 31
3 citations
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.
Muhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, Seongho Kim, Krish Patel, Nancy L Bartlett, Mary-Kate Malecek, Marcus P Watkins, Kami J Maddocks, David A Bond,...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Jul 1
Anti-spike antibody response to the COVID vaccine in lymphoma patients.
Alexandra Della Pia, Gee Youn Geeny Kim, Andrew Ip, Jaeil Ahn, Yanzhi Liu, Simone Kats, Michael Koropsak, Brittany Lukasik, Anamta Contractor, Krushna Amin, Lakshmi Ay...> ;Plos One. 2022 Jan 1
6 citations
Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma
Victor M. Orellana-Noia, Krista Isaac, Mary-Kate Malecek, Nancy L. Bartlett, Timothy J Voorhees, Natalie S Grover, Steven R. Hwang, N. Nora Bennani, Rachel Hu, Brian T...> ;Blood Advances. 2021 Sep 28
51 citations
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
Ranjana H. Advani, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren, Tatyana Feldman, Ann S. LaCasce, Beth A. Christian, Stephen M. Ans...> ;Blood. 2021 Aug 12
11 citations
HIV-associated Burkitt lymphoma: Outcomes from a US-UK collaborative analysis
Juan Pablo Alderuccio, Adam J. Olszewski, Andrew M. Evens, Graham P. Collins, Alexey V. Danilov, Mark Bower, Deepa Jagadeesh, Catherine Zhu, Amy Sperling, Seo-Hyun Kim...> ;Blood Advances. 2021 Jul 27
11 citations
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
Andrew M. Evens, Joseph M. Connors, Anas Younes, Stephen M. Ansell, Won Seog Kim, John Radford, Tatyana Feldman, Joseph Tuscano, Kerry J. Savage, Yasuhiro Oki, Andrew ...> ;Haematologica. 2021 Jun 24
36 citations
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 tr...
David J. Straus, Monika Długosz-Danecka, Joseph M. Connors, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech-Marańda, Tatyana Feldman, Piotr Smolewski, Kerry J. S...> ;The Lancet. Haematology. 2021 Jun 1
8 citations
Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation.
Alan P Skarbnik, Michele L. Donato, Rena Feinman, Scott D. Rowley, David H. Vesole, Andre Goy, Pashna N. Munshi, Tatyana Feldman, Lori A. Leslie, Noa Biran, Themba Nyi...> ;Transplantation and Cellular Therapy. 2021 May 1
15 citations
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.
Michele L. Donato, Steven I. Park, Melissa Baker, Robert Korngold, Alison Morawski, Xue Geng, Ming Tan, Andrew Ip, Stuart L. Goldberg, Scott D. Rowley, Kar F. Chow, Em...> ;JCI Insight. 2021 Mar 22
27 citations
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
Reid W. Merryman, Luca Castagna, Laura Giordano, Vincent T. Ho, Paolo Corradini, Anna Guidetti, Beatrice Casadei, David A. Bond, Samantha Jaglowski, Michael A. Spinner...> ;Leukemia. 2021 Mar 3
11 citations
Burkitt Lymphoma International Prognostic Index
Adam J. Olszewski, Lasse Hjort Jakobsen, Graham P. Collins, Kate Cwynarski, Veronika Bachanova, Kristie A. Blum, Kirsten M Boughan, Mark Bower, Alessia Dalla Pria, Ale...> ;Journal of Clinical Oncology. 2021 Jan 27
29 citations
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers
Andrew M. Evens, Alexey V. Danilov, Deepa Jagadeesh, Amy Sperling, Seo-Hyun Kim, Ryan Vaca, Catherine Wei, Daniel Rector, Suchitra Sundaram, Nishitha Reddy, Yong Lin, ...> ;Blood. 2021 Jan 21
27 citations
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2...
Bruce D. Cheson, Nancy L. Bartlett, Betsy LaPlant, Hun J Lee, Ranjana J Advani, Beth Christian, Catherine Diefenbach, Tatyana Feldman, Stephen M. Ansell> ;The Lancet. Haematology. 2020 Nov 1
4 citations
Patients With Natural Killer (NK) Cell Chronic Active Epstein-Barr Virus Have Immature NK Cells and Hyperactivation of PI3K/Akt/mTOR and STAT1 Pathways.
Matthew K. Howe, Kennichi C. Dowdell, Hye Sun Kuehn, Qingxue Li, Geoffrey T. Hart, Doreen Garabedian, Kelly Liepshutz, Amy P. Hsu, Hua Su, Julie E. Niemela, Jennifer S...> ;The Journal of Infectious Diseases. 2020 Sep 1
6 citations
Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL.
Tatyana Feldman, Denise Zou, Mayvis Rebeira, Joseph K. T. Lee, Michelle A. Fanale, Thomas Manley, Shangbang Rao, Joseph Feliciano, Mack Harris, Anuraag Kansal> ;The American Journal of Managed Care. 2020 Feb 1
15 citations
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.
Frederick Lansigan, Steven M. Horwitz, Lauren C. Pinter-Brown, Steven T. Rosen, Barbara Pro, Eric D. Hsi, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa...> ;Acta Haematologica. 2020 Jan 1
57 citations
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study
David J. Straus, Monika Długosz-Danecka, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech-Marańda, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bar...> ;Blood. 2019 Nov 13
2 citations
Contemporary management of nodal and primary splenic marginal zone lymphoma
Lori A. Leslie, Tatyana Feldman, Ann McNeill, Mary Timberg, Hoshiyuki Iida, Andre Goy> ;Expert Review of Hematology. 2019 Nov 12
19 citations
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Steven M. Bair, Lauren E. Strelec, Tatyana Feldman, Gulrayz Ahmed, Philippe Armand, Nirav N. Shah, Arun N. Singavi, Nishitha Reddy, Nadia Khan, Charalambos Andreadis, ...> ;The Oncologist. 2019 Jul 1
118 citations
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
Radhakrishnan Ramchandren, Eva Domingo-Domenech, Antonio Rueda, Marek Trněný, Tatyana Feldman, Hun Ju Lee, Mariano Provencio, Christian Sillaber, Jonathon B. Cohen, Ke...> ;Journal of Clinical Oncology. 2019 May 21
16 citations
Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma
Grzegorz S. Nowakowski, Tatyana Feldman, Lisa M. Rimsza, Jason R. Westin, Thomas E. Witzig, Pier Luigi Zinzani> ;Blood Cancer Journal. 2019 May 16
Join now to see all

Abstracts/Posters

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and C...
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malig...
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refracto...
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Cost-Effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma.
2019 ASCO Annual Meeting - 6/1/2019
Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

2022 N.J. Top Cancer Doctors Deliver Quality and Compassionate Care, Close to HomeJune 16th, 2022
N.J.’s 2021 Top Cancer Doctors Lead Charge to Help Patients Thrive and Survive After PandemicJune 17th, 2021
John Theurer Cancer Center's Dr. Andre Goy Co-Chairs 21st Annual International Congress on Hematologic MalignanciesFebruary 27th, 2017

Professional Memberships

American College of Physicians - ACP
Member
American Society of Hematology - ASH
Member
American Society of Clinical Oncology - ASCO
Member

Other Languages

Russian

Hospital Affiliations

Hackensack Meridian Health Hackensack University Medical CenterHackensack, New Jersey

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AmeriHealth Direct POS
Amerihealth HMO
AmeriHealth PPO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS PPO
GHI PPO
Great West PPO
Healthfirst New York
Horizon BCBS Direct Access
Horizon BCBS HMO
Horizon BCBS POS
Horizon BCBS PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment